Business Wire

PA-PPG

31.5.2023 16:16:25 CEST | Business Wire | Press release

Share
PPG sets science-based 2030 decarbonization targets, reports 2022 sustainability progress

PPG (NYSE:PPG) today announced its near-term 2030 sustainability goals, including greenhouse gas (GHG) emissions targets that have been validated by the Science Based Targets initiative (SBTi). The company also marked strong progress against its environmental, social and governance (ESG) priorities, reporting increased sales of sustainably advantaged products, more efficient operations, strong momentum towards achieving diversity, equity and inclusion goals, greater supplier sustainability and strengthened support within communities where the company operates.

“PPG has long been committed to reducing the environmental impact of its own operations, and we are proud to have validated science-based GHG emissions targets that are in line with the expectations of the Paris Agreement,” said Diane Kappas, PPG vice president, global sustainability. “By raising our sustainability ambitions and increasing sales of sustainable solutions for our customers, PPG is advancing its leadership in the paints and coatings industry.”

PPG has committed to reduce absolute emissions from its own operations (scope 1 and 2) by 50% by 2030 from a 2019 base year. It has also committed to reduce absolute scope 3 GHG emissions from purchased goods and services, processing of sold products, and end-of-life treatment of sold products by 30% within the same timeframe. The company’s emissions reduction strategy for its own operations includes energy efficiency projects and renewable energy sourcing. Within the value chain – or scope 3 – PPG is collaborating with suppliers to identify GHG emissions reduction opportunities and lower-carbon raw material sources. PPG recently signed an agreement with NRG Energy Inc. that will enable four PPG paints and coatings manufacturing facilities and 62 PPG PAINTS™ stores in Texas to operate on 100% renewable electricity.

In addition to its science-based emission targets, PPG’s other 2030 ESG targets against a 2019 baseline are:

  • 50% of sales from sustainably advantaged products
  • 15% reduction in water intensity at priority sites
  • 25% reduction in waste intensity
  • Reuse, recycle or recover 100% of process waste
  • $5 million additional COLORFUL COMMUNITIES® funding, with each project incorporating an element of sustainability, making the total investment $15 million since 2015
  • 100% of key suppliers assessed against sustainability and social responsibility criteria
  • 100% of employees go home safely each day
  • 5% annual reduction in spill and release rate

Furthermore, the company outlined key progress from the 2022 reporting year including:

  • Developing sustainable innovations that meet customers’ greatest needs, such as the launch of PPG INNOVEL® PRO, a non-bisphenol/non-BPA coating that ensures minimal spoilage and protection for aluminum beverage cans, while promoting circularity.
  • Collaborating with Steelcase, a U.S. manufacturer of architecture, furniture and technology products, to further increase the circularity of PPG powder coatings. PPG developed processes to recycle powder overspray into new coatings, which Steelcase uses on brackets, inside drawers and other less-visible surfaces in its products.
  • Continued investment in PPG’s signature Colorful Communities initiative. The company marked more than 470 projects, impacting more than 8 million people since 2015.
  • Strong improvement against 2025 diversity, equity and inclusion aspirational goals, including:
    • 19% increase in U.S. non-frontline Black headcount
    • 16% increase in U.S. non-frontline Latino headcount
    • 8% increase in U.S. non-frontline Asian headcount
    • 31% representation of non-frontline female professionals; a 180 basis-point improvement from 2021

“We remain committed to our journey of fostering a more diverse and inclusive community both within and beyond PPG,” said Marvin Mendoza, PPG global head, diversity, equity and inclusion. “We know that diverse teams perform better, and our 2022 progress is enabling a more equitable, inclusive future where employees feel even more empowered to bring their whole selves to work.”

Additional 2022 progress is outlined in further detail in PPG’s just-released 2022 Environmental, Social and Governance (ESG) Report at ppg.com/sustainability.

The Science Based Targets initiative (SBTi) mobilizes companies to set science-based targets and boost their competitive advantage in the transition to the low-carbon economy. It is a partnership between CDP, the United Nations Global Compact, World Resources Institute (WRI) and the World Wide Fund for Nature (WWF). The SBTi call to action is one of the We Mean Business Coalition commitments. The initiative defines and promotes best practice in science-based target setting, offers resources and guidance to reduce barriers to adoption, and independently assesses and approves companies’ targets.

PPG: WE PROTECT AND BEAUTIFY THE WORLD®

At PPG (NYSE:PPG), we work every day to develop and deliver the paints, coatings and specialty materials that our customers have trusted for 140 years. Through dedication and creativity, we solve our customers’ biggest challenges, collaborating closely to find the right path forward. With headquarters in Pittsburgh, we operate and innovate in more than 70 countries and reported net sales of $17.7 billion in 2022. We serve customers in construction, consumer products, industrial and transportation markets and aftermarkets. To learn more, visit www.ppg.com.

PPG Paints is a trademark and Colorful Communities, Innovel, the PPG Logo and We protect and beautify the world are registered trademarks of PPG Industries Ohio, Inc.

CATEGORY Sustainability

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230531005110/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye